CSIMarket Company Name, Ticker, Customers, else..
 
Avalo Therapeutics Inc   (NASDAQ: AVTX)
Other Ticker:  
 
 
Price: $7.5400 $-0.04 -0.528%
Day's High: $7.745 Week Perf: 11.7 %
Day's Low: $ 7.27 30 Day Perf: -15.38 %
Volume (M): 105 52 Wk High: $ 34.46
Volume (M$): $ 788 52 Wk Avg: $9.97
Open: $7.66 52 Wk Low: $4.01



 Market Capitalization (Millions $) 177
 Shares Outstanding (Millions) 24
 Employees 27
 Revenues (TTM) (Millions $) 1
 Net Income (TTM) (Millions $) -8
 Cash Flow (TTM) (Millions $) 72
 Capital Exp. (TTM) (Millions $) 0

Avalo Therapeutics Inc
Avalo Therapeutics Inc is a pharmaceutical company that focuses on developing novel cancer therapies. The company's primary aim is to develop treatments that can harness the body's immune system to fight against cancer, particularly in patients whose tumors exhibit resistance to existing therapies. Avalo Therapeutics is dedicated to advancing innovative immunotherapy approaches and discovering new targets for effective cancer treatment.


   Company Address: 540 Gaither Road, Suite 400 Rockville 20850 MD
   Company Phone Number: 522-8707   Stock Exchange / Ticker: NASDAQ AVTX


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
BGNE        1.21% 
BMY        1.21% 
REGN        1.21% 
TEVA        1.21% 
VRTX        1.21% 
VTRS        1.21% 
• View Complete Report
   



Clinical Study

Breaking Ground Avalos AVTX-009 Begins Phase 2 Journey, Offering New Hope for Hidradenitis Suppurativa Patie...

Published Tue, Oct 8 2024 11:00 AM UTC

Abstract: Avalo Therapeutics, Inc. has initiated its Phase 2 LOTUS trial, marking a significant advancement in the development of AVTX-009, a humanized monoclonal antibody aimed at treating hidradenitis suppurativa (HS). This article delves into the implications of AVTX-009 s mechanism of action, its potential benefits for patients with HS, and the significance of this mil...
Clinical Study

Avalo Therapeutics Sets the Stage for Breakthrough HS Treatment with Active IND for AVTX-009

Published Tue, Jul 9 2024 11:00 AM UTC

In a remarkable stride towards innovative treatment options for Hidradenitis Suppurativa (HS), Avalo Therapeutics, Inc. recently announced the active status of its Investigational New Drug (IND) application for AVTX-009. This development allows the biotechnology company to initiate its pivotal Phase 2 LOTUS clinical trial, aimed at exploring the efficacy of their anti-IL-1 m...
Shares

Avalo Therapeutics Welcomes Paul Varki as Chief Legal Officer, Shareholders Rejoice

Published Mon, Jun 24 2024 8:01 PM UTC


In a strategic move to further strengthen its leadership team, Avalo Therapeutics, Inc. (Nasdaq: AVTX) proudly announced the appointment of Paul Varki as its new Chief Legal Officer. Varki brings with him a wealth of experience and expertise in the legal field, positioning him as a valuable asset to the company s continued growth and success.
The appointment of Vark...
Avalo Therapeutics Inc

Avalo Therapeutics Inc shows strength through a consolidating first quarter of 2024 earnings season



Avalo Therapeutics, a biotechnology company specializing in novel cancer therapies, recently reported its financial results for the first quarter of 2024. While the figures indicate a loss in earnings compared to the previous year, there are several key factors to consider when assessing the impact on the company going forward.
Earnings Analysis:
For the first quarter of 2024, Avalo Therapeutics reported a loss of $-141.00 per share, an improvement from the $-204.00 loss per share recorded a year before. Furthermore, there was a significant increase in the shortfall from the previous financial reporting period, with the figure rising from $-8.50 per share.
Avalo Therapeutics Inc

Avalo Therapeutics Inc Turns Losses Around, Sees Positive Growth in Revenue

Avalo Therapeutics Inc, a leading biotechnology company specializing in novel cancer therapies, has recently released its year-end financial results for 2023. The company reported a decrease in loss per share from $-250.23 to $-8.50 compared to the previous year. This improvement in EPS was also seen when comparing it to the previous reporting period, where it increased from $-26.40 per share.
The revenue for Avalo Therapeutics Inc experienced a decline of -36.384% from $0.90 million to $0.57 million in the same reporting period a year ago. However, sequentially, the revenue doubled by 141.525% from $0.24 million. This indicates positive growth and potential for the company in the coming years.






Avalo Therapeutics Inc's Segments





Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com